[Ip-health] Youtube Video Competition on Need of New Drugs for TB

Gopa Kumar kumargopakm at gmail.com
Thu Nov 8 06:22:14 PST 2012


OSDD is organising a Youtube Video Competition on Need of New Drugs for TB.
Please find the relavant attachments.
There is also a blog written by me
http://scienceopenscience.blogspot.in/2012/10/normal-0-false-false-false-en-us-x-none.html
Following is the link to the call out video on the topic
http://www.youtube.com/watch?v=OA1Yl0Vf35E
Please participate and circulate this mail for wide participation.




[image: Logo]                 [image: vp.gif]





For more information, please contact:

OSDD: Zakir Thomas at +91-9868803002 or zthomas at osdd.org

Dr. D S Bedi at +91-9811615280 or bedids at csir.res.in

Vigyan Prasar: Dr T. V Vishwanathan at +91- 9810512077 or
tvv at vigyanprasar.gov.in







* *

*Press Release*

* *

*You Tube Based Short Video Competition *

*“The Need of New Drugs for TB”*



*New Delhi, India (17 October 2012) - *With the objective of bringing in
more eyeballs to focus on the bug *Mycobacterium tuberculosis*, and to
conscientize public regarding the urgent need of discovery of new drugs in
the wake of news of outbreaks of deadly drug-resistant TB in India,
CSIR-Open Source Drug Discovery, in collaboration with Vigyan Prasar is
announcing a YouTube based short video competition on the theme “*The Need
of New Drugs for TB”.*

* *

*Background  *

TB is a leading global killer, but its impact is felt hardest in India. WHO
estimates that each year, 2.3 million people in India contract TB, and
320,000 die from the disease. Over 1000 lives succumb to TB everyday (2
deaths every 3 minutes) in India. Existing TB treatment makes use of
combinatorial therapy involving 4 medicines (Isoniazid, Rifampicin,
Ethambutol, Pyrazinamide) and is administered for a period of 6 to 9 months
under the direct observation of a physician (DOTS). These drugs were
discovered in the middle of 20th century. The treatment regimen is too long
and risk prone and the inadequate administration of existing treatment has
resulted in the emergence of MDR (multiple drug resistant) TB and XDR
(extremely drug resistant) TB. India has the highest prevalence of
drug-resistant TB. Nearly 100,000 patients in India suffer from multi-drug
resistant TB (MDR-TB). Recent reports of 12 cases of a new class of
Extensively Drug Resistant (XDR) TB made national and international
headlines. This has raised serious concerns amongst the clinicians treating
TB who see themselves unarmed with drugs that can fight MDR- and XDR-TB.
Currently, someone with drug-sensitive TB must take a course of drugs for
six months, while those with MDR-TB must take an injection along with a
number of drugs for the first six months and continue that drug treatment
for 18 months or longer. Around the world, many patients fail to complete
treatment because they cannot tolerate the difficult side effects of the
medications and fail to adhere to the long treatment. This leads to the
development of drug resistance. Once infected with drug-resistant TB, that
disease can be spread directly to others. Treatment of drug-resistant TB is
exponentially more difficult and expensive than treatment of drug-sensitive
TB. Of the small numbers of patients who are able to access appropriate
treatment, mortality of 1 in 3 is common. The emergence of drug resistant
cases of TB, and lack of any new drugs since past 60 years, demands the urgent
discovery of more effective, novel drugs and TB regimens to control the TB
epidemic, prevent the growth and spread of drug resistance, and stop
needless deaths.

* *

*Objective*

This YouTube based short video aims at creating awareness regarding the
urgent need of new drug discovery for tuberculosis. TB is a growing problem
in India that demands special attention at every level for its control,
prevention, spread and cure.  It is indeed the need of the hour that
tuberculosis is recognized as the topmost priority research area by the
global scientific community. This contest intends to conscientize
individuals from every strata of the society towards the need and urgency
of development of new anti – TB therapies.

*Contest Details *

·       Contest Open now. **

·       Contest is open to all individuals (above 18 years) as well as
production agencies, organizations and educational institutes. Media
centres, television channels and media schools are also encouraged to
participate.  (In India only)

·       *Theme:* "The Need of New Drugs for Tuberculosis".

·       *Duration:* Not exceeding 5 minutes

·       *Mode of submission*: YouTube URLs / Email attachments / DVD or VCD

·       *Awards*

a. First Prize  50,000/-

b. Second Prize  25,000/-

c. Third Prize  15,000/-

d. 20 Merit Prizes  10,000/- each

·       *Contest closes*:  26th November 2012, 5.00 pm

·       The Award Ceremony will be held during the Indian Science Congress
2013 at NCSM, Headquarter, Kolkata on 7th January 2013.



For terms and conditions and to download the entry form please visit:
www.osdd.net or www.vigyanprasar.gov.in**

* *

*About the Council of Scientific and Industrial Research (CSIR): *

Council of Scientific and Industrial Research (CSIR) is an autonomous
society whose President is the      Prime Minister of India. CSIR is an
ensemble of 37 laboratories in engineering, physical, biological, chemical
and information science clusters, funded chiefly by the government of
India. CSIR laboratories engage about 5000 scientists and almost 10000
students pursuing higher degrees.



* *

*About the Open Source Drug Discovery Program (OSDD):*

Open Source Drug Discovery (OSDD) is an initiative funded and led by the
Council of Scientific and Industrial Research, an autonomous body under the
Government of India.  CSIR provides scientific and industrial R&D that
maximizes the economic, environmental and societal benefits for the people
of India. OSDD is a team India consortium with global partnership with a
vision to provide affordable healthcare to the developing world to solve
the complex problems associated with discovering novel therapies for
diseases like Tuberculosis, Malaria and Leishmaniasis.



For more information please visit www.osdd.net



*About Vigyan Prasar (VP):*

Vigyan Prasar (VP) is an autonomous organization under Department of
Science and Technology.  VP aims at taking up large-scale science
popularization tasks/activities with the vision to promote and propagate
scientific and rational outlook and act as a resource-cum-facility centre
for S&T communication. VP strives to adapt, utilize and employ new and
emerging technologies for S&T communication / popularization and aims at
development of a countrywide network for S&T popularization / communication.

For more information, please visit: www.vigyanprasar.gov.in



More information about the Ip-health mailing list